Suppression of plasma androgen levels with a combination therapy of depot-estrogen (Turisteron) and Dexamethasone in patients with prostatic cancer.
Treatment of patients with prostatic cancer with a combination of 1-2 mg depot-estrogen (ethinylestradiol sulfonate = Turisteron) per week and 1 mg dexamethasone per day suppressed the mean testosterone (T) level to 2.8% (0.53 nmol/l), the free T to 0.8% (1.9 pmol/l) and the adrenal androgens (AA) -- androstenedione (A), dehydroepiandrosterone (DHEA) and its sulfate (DHEAS) -- to more than 40% of the initial values. Treatment with Turisteron alone (2 mg per week) did not change the DHEA and DHEAS levels but decreased plasma A concentration to 65% (2.96 nmol/l) of the initial values.
Stahl
F
F
Institute of Experimental Endocrinology, Humboldt University Medical School (Charité), Berlin/GDR.
Schnorr
D
D
Bär
C M
CM
Fröhlich
G
G
Dörner
G
G
D000368:Aged; D000369:Aged, 80 and over; D000728:Androgens / Q000097:blood*; D003907:Dexamethasone / Q000494:pharmacology*; D004359:Drug Therapy, Combination; D004997:Ethinyl Estradiol / Q000031:analogs & derivatives* / Q000494:pharmacology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000097:blood* / Q000188:drug therapy
D000728:Androgens; C025723:ethinyl estradiol sulfonate; D004997:Ethinyl Estradiol; D003907:Dexamethasone